Redeye re-initiates coverage of Xvivo with strengthened conviction following a deep dive into its clinical data and that of key competitor TransMedics, as well as target markets. While the coronavirus crisis presents some nearer-term challenges, the case is attractive in view of Xvivo’s commercial and clinical progress, strong positioning for a surgical pick-up and undemanding valuation even after the share’s recent rebound.